Zhejiang East Asia Pharmaceutical Co., Ltd. (SHA:605177)
China · Delayed Price · Currency is CNY 23.44
+0.64 (2.81%)
Sep 2, 2026, 3:00 PM CST
SHA:605177 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 956.47 | 906.19 | 1,188 | 1,351 | 1,174 | 702.06 |
Other Revenue | 34 | 34 | 9.76 | 5.86 | 5.28 | 10.16 |
| 990.47 | 940.19 | 1,198 | 1,356 | 1,180 | 712.22 | |
Revenue Growth | 2.55% | -21.54% | -11.66% | 15.00% | 65.62% | -19.22% |
Cost of Revenue | 828.17 | 763.82 | 1,004 | 1,008 | 913.49 | 521.62 |
Gross Profit | 162.3 | 176.37 | 194.21 | 348.75 | 266.06 | 190.6 |
Selling, General & Admin | 191.5 | 170.21 | 179.97 | 146.85 | 122.72 | 116.33 |
Research & Development | 87.26 | 86.76 | 117.02 | 81.74 | 44.95 | 37.29 |
Other Operating Expenses | 10.75 | 6.75 | 6.27 | 5.6 | 8.57 | 5.2 |
Operating Expenses | 289.38 | 263.6 | 304.11 | 236.91 | 177.54 | 157.81 |
Operating Income | -127.08 | -87.23 | -109.91 | 111.84 | 88.52 | 32.79 |
Interest Expense | -17.35 | -17.35 | -2.04 | -3.6 | -0.84 | -0.22 |
Interest & Investment Income | 8.31 | 7.61 | 9.62 | 18.26 | 21.27 | 28.97 |
Currency Exchange Gain (Loss) | 0.47 | 0.47 | 3.13 | 0.8 | 2.22 | -0.68 |
Other Non Operating Income (Expenses) | -14.4 | -0.77 | -1.09 | -0.82 | -0.51 | -0.56 |
EBT Excluding Unusual Items | -150.05 | -97.27 | -100.29 | 126.48 | 110.66 | 60.3 |
Gain (Loss) on Sale of Assets | -3.09 | -3.19 | -15.56 | -5.69 | -5.54 | -4.05 |
Asset Writedown | -41.05 | -1.73 | -11.37 | - | - | - |
Other Unusual Items | 13.62 | 13.62 | 9.05 | 13.9 | 9.97 | 20.81 |
Pretax Income | -180.57 | -88.57 | -118.17 | 134.69 | 115.09 | 77.06 |
Income Tax Expense | -10.03 | -6.14 | -17.47 | 13.44 | 10.67 | 8.57 |
Earnings From Continuing Operations | -170.54 | -82.43 | -100.7 | 121.25 | 104.43 | 68.49 |
Minority Interest in Earnings | 0 | 0.04 | 0.04 | - | - | - |
Net Income | -170.54 | -82.39 | -100.66 | 121.25 | 104.43 | 68.49 |
Net Income to Common | -170.54 | -82.39 | -100.66 | 121.25 | 104.43 | 68.49 |
Net Income Growth | - | - | - | 16.11% | 52.46% | -40.17% |
Shares Outstanding (Basic) | 114 | 114 | 112 | 113 | 114 | 114 |
Shares Outstanding (Diluted) | 114 | 114 | 112 | 125 | 114 | 114 |
Shares Change | -0.19% | 2.31% | -10.52% | 10.13% | -0.57% | 30.62% |
EPS (Basic) | -1.50 | -0.72 | -0.90 | 1.07 | 0.92 | 0.60 |
EPS (Diluted) | -1.50 | -0.72 | -0.90 | 0.97 | 0.92 | 0.60 |
EPS Growth | - | - | - | 5.44% | 53.33% | -54.20% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -24.42 | -343.11 | -368.16 | -311.53 | -158.17 | -145.57 |
Free Cash Flow Per Share | -0.21 | -3.00 | -3.29 | -2.49 | -1.39 | -1.27 |
Dividend Per Share | - | - | - | 0.327 | 0.290 | 0.200 |
Dividend Growth | - | - | - | 12.63% | 45.00% | -42.86% |
Gross Margin | 16.39% | 18.76% | 16.21% | 25.71% | 22.56% | 26.76% |
Operating Margin | -12.83% | -9.28% | -9.17% | 8.24% | 7.51% | 4.60% |
Profit Margin | -17.22% | -8.76% | -8.40% | 8.94% | 8.85% | 9.62% |
Free Cash Flow Margin | -2.46% | -36.49% | -30.73% | -22.97% | -13.41% | -20.44% |
EBITDA | 45.32 | 64.36 | 22.33 | 220.24 | 180.68 | 101.97 |
EBITDA Margin | 4.58% | 6.85% | 1.86% | 16.24% | 15.32% | 14.32% |
D&A For EBITDA | 172.4 | 151.59 | 132.24 | 108.4 | 92.15 | 69.18 |
EBIT | -127.08 | -87.23 | -109.91 | 111.84 | 88.52 | 32.79 |
EBIT Margin | -12.83% | -9.28% | -9.17% | 8.24% | 7.51% | 4.60% |
Effective Tax Rate | - | - | - | 9.98% | 9.27% | 11.12% |
Revenue as Reported | 940.19 | 940.19 | 1,198 | 1,356 | 1,180 | 712.22 |
Advertising Expenses | - | 3.24 | 3.23 | 2.5 | 0.08 | 1.74 |